VestGen Advisors LLC Has $7.47 Million Position in AbbVie Inc. $ABBV

VestGen Advisors LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 31.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 39,724 shares of the company’s stock after acquiring an additional 9,564 shares during the period. VestGen Advisors LLC’s holdings in AbbVie were worth $7,472,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC increased its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Alberta Investment Management Corp increased its stake in shares of AbbVie by 1,248.4% during the 1st quarter. Alberta Investment Management Corp now owns 64,725 shares of the company’s stock worth $13,561,000 after purchasing an additional 59,925 shares during the last quarter. SPC Financial Inc. bought a new position in shares of AbbVie during the 1st quarter valued at $254,000. Finally, IFG Advisory LLC lifted its stake in shares of AbbVie by 2.3% in the 1st quarter. IFG Advisory LLC now owns 38,404 shares of the company’s stock valued at $8,046,000 after purchasing an additional 880 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV opened at $226.72 on Friday. The firm has a market capitalization of $400.69 billion, a P/E ratio of 107.96, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The stock’s 50 day moving average price is $227.71 and its two-hundred day moving average price is $206.80. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the company earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s payout ratio is currently 524.24%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABBV. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. BMO Capital Markets increased their price objective on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Daiwa Capital Markets upgraded AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.